1. Home
  2. PBM vs GRI Comparison

PBM vs GRI Comparison

Compare PBM & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBM
  • GRI
  • Stock Information
  • Founded
  • PBM 1994
  • GRI 2018
  • Country
  • PBM Canada
  • GRI United States
  • Employees
  • PBM N/A
  • GRI N/A
  • Industry
  • PBM
  • GRI Biotechnology: Pharmaceutical Preparations
  • Sector
  • PBM
  • GRI Health Care
  • Exchange
  • PBM NYSE
  • GRI Nasdaq
  • Market Cap
  • PBM 5.3M
  • GRI 5.6M
  • IPO Year
  • PBM N/A
  • GRI N/A
  • Fundamental
  • Price
  • PBM $1.30
  • GRI $0.42
  • Analyst Decision
  • PBM
  • GRI Strong Buy
  • Analyst Count
  • PBM 0
  • GRI 2
  • Target Price
  • PBM N/A
  • GRI $11.50
  • AVG Volume (30 Days)
  • PBM 367.3K
  • GRI 181.8K
  • Earning Date
  • PBM 02-02-2025
  • GRI 03-27-2025
  • Dividend Yield
  • PBM N/A
  • GRI N/A
  • EPS Growth
  • PBM N/A
  • GRI N/A
  • EPS
  • PBM N/A
  • GRI N/A
  • Revenue
  • PBM N/A
  • GRI N/A
  • Revenue This Year
  • PBM N/A
  • GRI N/A
  • Revenue Next Year
  • PBM N/A
  • GRI N/A
  • P/E Ratio
  • PBM N/A
  • GRI N/A
  • Revenue Growth
  • PBM N/A
  • GRI N/A
  • 52 Week Low
  • PBM $1.15
  • GRI $0.30
  • 52 Week High
  • PBM $323.25
  • GRI $12.31
  • Technical
  • Relative Strength Index (RSI)
  • PBM 38.56
  • GRI 28.18
  • Support Level
  • PBM $1.15
  • GRI $0.43
  • Resistance Level
  • PBM $1.47
  • GRI $0.60
  • Average True Range (ATR)
  • PBM 0.13
  • GRI 0.06
  • MACD
  • PBM 0.04
  • GRI -0.00
  • Stochastic Oscillator
  • PBM 34.09
  • GRI 10.91

About PBM PSYENCE BIOMEDICAL LTD

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: